Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Stock Information for Eloxx Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eloxx Pharmaceuticals Inc.

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.